company background image
SLGL

Sol-Gel TechnologiesNasdaqGM:SLGL Stock Report

Last Price

US$7.49

Market Cap

US$173.2m

7D

-8.8%

1Y

-28.3%

Updated

18 Jan, 2022

Data

Company Financials +
SLGL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SLGL Stock Overview

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.

Sol-Gel Technologies Competitors

Verrica Pharmaceuticals

NasdaqGM:VRCA

US$220.4m

Journey Medical

NasdaqCM:DERM

US$84.0m

VYNE Therapeutics

NasdaqGS:VYNE

US$36.9m

Sun Pharmaceutical Industries

NSEI:SUNPHARMA

₹2.0t

Price History & Performance

Summary of all time highs, changes and price drops for Sol-Gel Technologies
Historical stock prices
Current Share PriceUS$7.49
52 Week HighUS$16.69
52 Week LowUS$6.12
Beta1.21
1 Month Change4.17%
3 Month Change-19.89%
1 Year Change-28.26%
3 Year Change28.92%
5 Year Changen/a
Change since IPO-45.09%

Recent News & Updates

Nov 23
We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Drive Business Growth

We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

SLGLUS PharmaceuticalsUS Market
7D-8.8%-3.5%-3.5%
1Y-28.3%7.1%10.2%

Return vs Industry: SLGL underperformed the US Pharmaceuticals industry which returned 9% over the past year.

Return vs Market: SLGL underperformed the US Market which returned 13.7% over the past year.

Price Volatility

Is SLGL's price volatile compared to industry and market?
SLGL volatility
SLGL Average Weekly Movement8.0%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.6%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: SLGL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: SLGL's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199765Alon Seri-Levyhttps://www.sol-gel.com

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products.

Sol-Gel Technologies Fundamentals Summary

How do Sol-Gel Technologies's earnings and revenue compare to its market cap?
SLGL fundamental statistics
Market CapUS$173.16m
Earnings (TTM)-US$17.30m
Revenue (TTM)US$12.52m

13.8x

P/S Ratio

-10.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SLGL income statement (TTM)
RevenueUS$12.52m
Cost of RevenueUS$21.05m
Gross Profit-US$8.53m
ExpensesUS$8.77m
Earnings-US$17.30m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.75
Gross Margin-68.13%
Net Profit Margin-138.14%
Debt/Equity Ratio0%

How did SLGL perform over the long term?

See historical performance and comparison

Valuation

Is Sol-Gel Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SLGL ($7.49) is trading below our estimate of fair value ($25.84)

Significantly Below Fair Value: SLGL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SLGL is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: SLGL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SLGL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SLGL is overvalued based on its PB Ratio (4.2x) compared to the US Pharmaceuticals industry average (2.3x).


Future Growth

How is Sol-Gel Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

54.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLGL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLGL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLGL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SLGL's revenue (20.3% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: SLGL's revenue (20.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SLGL's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Sol-Gel Technologies performed over the past 5 years?

0.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SLGL is currently unprofitable.

Growing Profit Margin: SLGL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SLGL is unprofitable, but has reduced losses over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare SLGL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLGL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: SLGL has a negative Return on Equity (-41.74%), as it is currently unprofitable.


Financial Health

How is Sol-Gel Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: SLGL's short term assets ($48.1M) exceed its short term liabilities ($9.5M).

Long Term Liabilities: SLGL's short term assets ($48.1M) exceed its long term liabilities ($1.9M).


Debt to Equity History and Analysis

Debt Level: SLGL is debt free.

Reducing Debt: SLGL currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLGL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SLGL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Sol-Gel Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SLGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SLGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SLGL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLGL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SLGL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

Alon Seri-Levy (60 yo)

25yrs

Tenure

US$636,000

Compensation

Dr. Alon Seri-Levy is a Co-Founder at Sol-Gel Technologies Ltd. in 1997 and has been its Chief Executive Officer since 1997. Dr. Seri-Levy established the computer-aided drug design department at Peptor Lt...


CEO Compensation Analysis

Compensation vs Market: Alon's total compensation ($USD636.00K) is below average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Alon's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SLGL's management team is seasoned and experienced (5.4 years average tenure).


Board Members

Experienced Board: SLGL's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sol-Gel Technologies Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sol-Gel Technologies Ltd.
  • Ticker: SLGL
  • Exchange: NasdaqGM
  • Founded: 1997
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$173.162m
  • Shares outstanding: 23.12m
  • Website: https://www.sol-gel.com

Number of Employees


Location

  • Sol-Gel Technologies Ltd.
  • 7 Golda Meir Street
  • Weizmann Science Park
  • Ness Ziona
  • 7403650
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/18 23:55
End of Day Share Price2022/01/18 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.